Key result
Myofibroblast-derived exosomes reduced Cav1.2 expression and attenuated adrenergic-elicited Ca2+ influx in cardiomyocytes, contributing to increased vulnerability to atrial fibrillation.
Why the study?
Whether exosome-mediated crosstalk between myofibroblasts and cardiomyocytes regulates Cav1.2 expression in the setting of atrial fibrosis and atrial fibrillation remains unknown.
Does treatment with myofibroblast-derived exosomes reduce Cav1.2 expression in neonatal rat cardiomyocytes?
Does treatment with myofibroblast-derived exosomes reduce Cav1.2 expression in neonatal rat cardiomyocytes?
Myofibroblast-derived exosomes reduce Cav1.2 expression in cardiomyocytes via miR-21-3p, contributing to an arrhythmogenic substrate for atrial fibrillation.
Suggests exosome-mediated AF substrate formation; hypothesis-generating and requires in vivo validation before any clinical consideration.
Objective: Atrial fibrosis plays a critical role in atrial fibrillation (AF). A key event in the pathogenesis of fibrosis is the activation of fibroblasts (FBs) into myofibroblasts (MFBs). Paracrine factors released from MFBs lead to ion channel expression changes in cardiomyocytes (CMs). Downregulation of L-type calcium channel Cav1.2 expression is a hallmark of AF-associated ionic remodeling. However, whether exosome (Exo)-mediated crosstalk between MFBs and CMs regulates Cav1.2 expression remains unknown. Methods: Atrial FBs and CMs were isolated and cultured from neonatal rats by enzymatic digestion. The activation of FBs into MFBs was induced by angiotensin II. Co-culture assay and in vitro Exo treatment were used to determine the effect of MFB-derived Exos on Cav1.2 expression. Confocal Ca²⁺ imaging was performed to examine the adrenergic stimulation-elicited Ca²⁺ influx signals. The levels of potential Cav1.2-inhibitory microRNAs (miRNAs) were measured by qRT-PCR. Results: Untreated FBs expressed limited amounts of alpha smooth muscle actin (α-SMA), while angiotensin II induced a significant upregulation of α-SMA-expressing MFBs. Co-cultures of MFBs and CMs resulted in downregulation of Cav1.2 expression in CMs, which was largely abolished by pretreatment of MFBs with exosomal inhibitor GW4869. More importantly, treatment with MFB-derived Exos caused repression of Cav1.2 expression in CMs. Additionally, the adrenergic receptor agonist-elicited Ca²⁺ influx signals in CMs were remarkably attenuated by pretreatment with MFB-derived Exos, corresponding to the paralleled change in Cav1.2 expression. Finally, miR-21-3p, a potential Cav1.2-inhibitory miRNA, was enriched in MFB-derived Exos and upregulated in CMs in response to MFB-derived Exos. Conclusion: We uncover an Exo-mediated crosstalk between MFBs and CMs, contributing to increased vulnerability to AF by reducing the expression of Cav1.2 in CMs.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied Atrial fibrillation. Myofibroblast-derived exosomes vs. Untreated fibroblasts or exosomal inhibitor GW4869 was evaluated on Cav1.2 expression and Ca2+ influx signals in cardiomyocytes. Myofibroblast-derived exosomes reduced Cav1.2 expression and attenuated adrenergic-elicited Ca2+ influx in cardiomyocytes, contributing to increased vulnerability to atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: